- Lifecore Biomedical and PolyPeptide Laboratories have announced a U.S.-focused collaboration to provide an integrated, end-to-end peptide drug development and manufacturing solution.
- The partnership combines peptide synthesis, formulation, fill/finish, and packaging services to accelerate development timelines and enhance supply chain reliability.
Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organisation (CDMO), has entered into a collaboration agreement with PolyPeptide Laboratories, Inc., a global peptide CDMO, to establish a unified service offering for peptide-based pharmaceutical developers in the United States.
The collaboration brings together PolyPeptide’s expertise in peptide development and manufacturing with Lifecore’s formulation, fill/finish, and packaging capabilities. The partnership aims to create a seamless transition between drug substance and drug product, supporting pharmaceutical companies with accelerated development, reduced costs, and enhanced supply chain reliability within the U.S. market.
“This collaboration brings together two leading organisations, each an expert in its field, to deliver value to peptide-based pharmaceutical developers. Together, we expect to optimise product development activities through a range of collaborative studies and assessments, and by streamlining the supply chain, aim to help customers meet their development milestones.”
Mark DaFonseca, Chief Commercial Officer at Lifecore Biomedical
According to PolyPeptide, the companies will work jointly on laboratory transfers, equipment comparability, method transfer, and release testing to ensure technical alignment and robust quality oversight across all project stages. “By aligning our technical and commercial strengths, we believe we are uniquely positioned to help customers navigate complex development challenges and bring innovative therapies to market faster,” said Trishul Shah, Global Director of Business Development and Head of Sales at PolyPeptide.
